Search

Your search keyword '"Naclerio, Robert M."' showing total 414 results
Start Over Author "Naclerio, Robert M." Publication Type Academic Journals
414 results on '"Naclerio, Robert M."'

1. Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.

Author

Ansotegui, Ignacio J., Bousquet, Jean, Canonica, Giorgio Walter, Demoly, Pascal, Gómez, Rene Maximiliano, Meltzer, Eli O., Murrieta-Aguttes, Margarita, Naclerio, Robert M., Rosario Filho, Nelson, and Scadding, Glenis K.

Subjects
POSITRON emission tomography, PSYCHOLOGY of movement, RANDOMIZED controlled trials, CENTRAL nervous system, ALLERGIES
Abstract

Fexofenadine is a second-generation inverse agonist of H1-receptor of histamine which is highly selective with proven efficacy in relieving symptoms associated with allergic conditions. It has an additional benefit of not penetrating the blood–brain barrier and therefore do not induce sedation and not impair the cognitive function/psychomotor performance. This review aimed at providing evidence based on available controlled studies to reinforce the non-sedative property of fexofenadine for treating patients with allergic rhinitis and urticaria. We performed an electronic literature search using keywords such as fexofenadine, drowsiness, somnolence, sedation, fatigue, cognitive, impairment, psychomotor, driving performances, sleep, rapid eye movement, alertness, clinical study, in vitro study, in vivo study, and pharmacodynamics in the Embase search engine. The review included randomized controlled trials, review articles, systematic reviews, and meta-analyses, together with post-marketing analysis conducted in healthy subjects and patients with allergy and were focused on comparing the antihistaminic potential or safety of fexofenadine with other antihistamines or placebo. Positron emission tomography (PET) and proportional impairment ratio (PIR) data along with other objective tests from various studies confirmed the non-sedative property of fexofenadine. Results of brain H1-receptor occupancy (H1RO) obtained from PET showed no H1RO by fexofenadine, the receptor which is known to cause sedation of H1 antihistamines. Most studies calculating PIR value as 0 showed fexofenadine to be a non-impairing oral antihistamine regardless of dose. Clinical trials in adults and children showed fexofenadine to be well tolerated without sedative effect or impairment of cognitive/psychomotor function even at higher than recommended doses. Published literature based on various parameters and clinical trials conducted for evaluating the effect of fexofenadine on sedation and central nervous system shows fexofenadine is both clinically effective and non-sedating. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

Author

Bachert, Claus, Mannent, Leda, Naclerio, Robert M., Mullol, Joaquim, Ferguson, Berrylin J., Gevaert, Philippe, Hellings, Peter, Jiao, Lixia, Wang, Lin, Evans, Robert R., Pirozzi, Gianluca, Graham, Neil M., Swanson, Brian, Hamilton, Jennifer D., Radin, Allen, Gandhi, Namita A., Stahl, Neil, Yancopoulos, George D., and Sutherland, E. Rand

Published
2016
Full Text
View/download PDF

12. Pharmacokinetic Evidence of Steady and Sustained Drug Release from Long-Acting Implantable Corticosteroid Matrices for Chronic Rhinosinusitis.

Author

Ow, Randall A., Shotts, Steven, Kakarlapudi, Venkata, McIntyre, John, Naclerio, Robert M., You, Changcheng, Pappas, Alexander, Brayton, Lindsay, Kuang, Yina, and Shao, James

Subjects
LIQUID chromatography-mass spectrometry, NASAL mucosa, SINUSITIS, PHARMACOKINETICS, NASAL cavity
Abstract

Background: The efficacy of topical corticosteroids is limited in chronic rhinosinusitis (CRS) due to rapid clearance from the nasal cavity and insufficient drug delivery to inflamed sinonasal passages. LYR-210 is an implantable corticosteroid matrix designed to provide up to 24 weeks of treatment to patients with CRS by locally delivering mometasone furoate (MF) to the sinonasal mucosa. In a randomized, controlled, dose-ranging LANTERN study, LYR-210 (7500 µg) achieved clinically relevant improvement in CRS cardinal symptom composite scores, the 22-item Sinonasal Outcome Test (SNOT-22), ethmoid opacification, and the need for rescue treatment at 24 weeks. Objective: As the plasma MF concentrations of LYR-210 (2500 µg) and LYR-210 (7500 µg) were evaluated at weeks 4, 12, and 24 in the LANTERN study (data on file at Lyra Therapeutics, Inc.), this study aims to characterize the pharmacokinetic profiles of both doses of LYR-210 at earlier timepoints post-placement in patients with CRS. Methods: Twenty-four surgically naïve adult patients with CRS were enrolled in an open-label, multicenter study and underwent in-office bilateral administration of LYR-210 (2500 µg) (n = 12 patients) or LYR-210 (7500 µg) (n = 12 patients) into the middle meatus. Plasma MF concentrations were determined pre-placement and 1-h post-placement (day 1), and on days 2, 3, 7, 14, 21, 28, 42, and 56 by liquid chromatography-tandem mass spectrometry. Results: Both LYR-210 doses were well-tolerated with no serious adverse events. Systemic MF levels were dose-dependent and lower than reported values of other respiratory MF products. Plasma MF concentrations showed steady drug release from LYR-210 (2500 µg) and LYR-210 (7500 µg) that persisted through day 56. Conclusion: LYR-210 achieved dose-dependent, continuous local MF delivery at a steady rate with low systemic exposure for months. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Rhinosinusitis: Developing guidance for clinical trials

Author

Meltzer, Eli O., Hamilos, Daniel L., Hadley, James A., Lanza, Donald C., Marple, Bradley F., Nicklas, Richard A., Adinoff, Allen D., Bachert, Claus, Borish, Larry, Chinchilli, Vernon M., Danzig, Melvyn R., Ferguson, Berrylin J., Fokkens, Wytske J., Jenkins, Stephen G., Lund, Valerie J., Mafee, Mahmood F., Naclerio, Robert M., Pawankar, Ruby, Ponikau, Jens U., Schubert, Mark S., Slavin, Raymond G., Stewart, Michael G., Togias, Alkis, Wald, Ellen R., and Winther, Birgit

Published
2006
Full Text
View/download PDF

37. Complications of nasal SARS-CoV-2 testing: a review.

Author

Clark, James H., Pang, Sharon, Naclerio, Robert M., and Kashima, Matthew

Abstract

Transnasal swab testing for the detection of SARSCoV-2 is well established. The Centers for Disease Control and Prevention advocates swabbing either of the anterior nares, middle turbinate, or nasopharynx for specimen collection depending on available local resources. The purpose of this review is to investigate complications related to transnasal SARS-CoV-2 testing with specific attention to specimen collection site and swab approach. The literature demonstrates that while nasopharyngeal swabbing is associated with an increased risk of complications, it should remain the gold-standard test due to greater diagnostic accuracy relative to anterior nasal and middle turbinate swabs. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results